Dec. 16, 2019: Salarius Pharmaceuticals announced that its lead investigational drug candidate, Seclidemstat(a potent reversible LSD1 inhibitor), has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Ewing sarcoma for the patients who have relapsed or are refractory to standard-of-care therapy.
Ewing sarcoma is a rare and deadly bone cancer that most often strikes children and young adults, for which there are no targeted therapies approved, Seclidemstat has demonstrated a potential to address this significant unmet need. https://fda.einnews.com/pr_news/504993934/salarius-pharmaceuticals-receives-fda-fast-track-designation-for-lead-drug-candidate-seclidemstat-in-relapsed-or-refractory-ewing-sarcoma
